Given the proven effectiveness of BCL‐2 inhibitor in combination with hypomethylating agents in AML, including EM involvement [5, 6, 7], and the intense diffuse positivity for BCL‐2, the patient was treated with Decitabine 20 mg/mq/day for 5 days plus Venetoclax at the dosage of 400 mg/day, together with antibacterial and antifungal oral prophylaxis. This evidence concerns the gene BCL2 and acute myeloid leukemia.